SteadyMed prices IPO at $8.50, below the range
SteadyMed, which is developing a proprietary pump system for the treatment of PAH and pain, raised $40 million by offering 4.7 million shares at $8.50, below the range of $12 to $14. SteadyMed will list on the NASDAQ under the symbol STDY. Wells Fargo Securities and RBC Capital Markets acted as joint bookrunners on the deal.
The article SteadyMed prices IPO at $8.50, below the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.